Navigation Links
Lupus Research Institute strategy delivers $30 million in national funding

NEW YORK, NY The Lupus Research Institute (LRI) strategy of backing innovative investigations into systemic lupus, the autoimmune disease, has now yielded an unprecedented $30 million in large-scale funding from the National Institutes of Health and other government and private sources, an independent progress report has determined.

To date, 36 scientists have completed their novel research grants from the 7-year-old LRIan Institute investment of $9 million. A remarkable 61% of these investigators have now turned their innovative hypotheses into confirmed discoveries, winning $30 million in large-scale grants to advance new scientific approaches to how and why lupus occurs, and what can be done to prevent and treat it.

The LRI has been the leader in seeking and funding unproven but promising scientific hypotheses in lupus, said Mark Shlomchik, MD, PhD, professor of Laboratory Medicine and Immunology at Yale University School of Medicine and a member of the LRI Scientific Advisory Board. Its because the LRI supported these innovative ideas in the first place that successful competition for scarce federal funding was possible.

An estimated 1.5 million Americans, and millions more worldwide, have lupus. Many are young women in the prime of their lives. No one knows why lupus occurs, or how to prevent or cure it. There hasnt been a new treatment approved for lupus in nearly 50 years, and existing medications are often toxic and can have debilitating effects.

LRI Breakthrough Discoveries in Lupus

Since its inception 7 years ago, the Institute has invested $22 million overall in cutting-edge lupus research, and current LRI-supported investigators are poised to capture similar large-scale awards. The Institute supports scientists from wide-ranging specialties who might otherwise not receive funds for their innovative and untested hypotheses in lupus.

In a brief time, LRI scientists have made breakthrough discoveries in such diverse fields as genetics, molecular science, cardiovascular disease, kidney disease, cognitive science, biomarkers, and pathways to autoimmune attack. Discoveries include:

  • 20 potential lupus biomarkers early predictors of disease and treatment effectiveness; six are now in clinical investigation and human testing.
  • Genes that increase susceptibility to lupus
  • Pathways that enable misguided antibodies to attack
  • Molecules that determine control of the immune system
  • Targets for new treatments
  • Insights on how lupus damages organs the heart, kidneys, brain, skin

Im grateful to the LRI for being brave enough to fund unusual work at an early stage of development, said Philip Cohen, MD, of the University of Pennsylvania, who received an LRI research grant in 2001 and is continuing his investigations. This initial funding was responsible for getting what is now a very large project off the ground.


Contact: Liane Stegmaier
Lupus Research Institute

Related biology news :

1. Study identifies genetic risk factor for rheumatoid arthritis, lupus
2. Research shows skeleton to be endocrine organ
3. Newly created cancer stem cells could aid breast cancer research
4. Dominant cholesterol-metabolism ideas challenged by new research
5. Researchers identify proteins involved in new neurodegenerative syndrome
6. Texas researchers and educators head for Antarctica
7. MGH researchers describe new way to identify, evolve novel enzymes
8. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
9. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
10. U of MN researchers discover noninvasive diagnostic tool for brain diseases
11. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
Post Your Comments:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology: